Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 479Lymphoid 4Sarcoma 1Genitourinary 1

Conditions

Prostatic Neoplasms 5016Carcinoma, Renal Cell 1574Urinary Bladder Neoplasms 1279Kidney Neoplasms 723Breast Neoplasms 642Neoplasms 628Carcinoma, Transitional Cell 487Neoplasm Metastasis 468Carcinoma, Non-Small-Cell Lung 467Melanoma 421Ovarian Neoplasms 399Colorectal Neoplasms 370Lung Neoplasms 333Pancreatic Neoplasms 262Sarcoma 231Stomach Neoplasms 226Uterine Cervical Neoplasms 223Testicular Neoplasms 215Non-Muscle Invasive Bladder Neoplasms 214Head and Neck Neoplasms 192Squamous Cell Carcinoma of Head and Neck 187Colonic Neoplasms 167Carcinoma, Hepatocellular 165Esophageal Neoplasms 164Endometrial Neoplasms 164Wilms Tumor 159Recurrence 131Triple Negative Breast Neoplasms 128Neuroblastoma 127Small Cell Lung Carcinoma 125

Interventions

MLN 8237 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Solid Tumors × Genitourinary × Clear all
NCT01094288 2019-02-15

A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen

Takeda

Phase 1 Completed
41 enrolled 31 charts
GenitourinaryOther solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡